Riabni

Amgen Inc🇺🇸 United States

FDA Page

Effective Date: Jul 22, 2026
Approval ID: da1c4de7-0e5b-4f72-97ec-7a8d368f085f
Products: 2 registered
Version: 12

Regulatory Information

Labeling Type

HUMAN PRESCRIPTION DRUG LABEL

Status

Approved

Full Title

These highlights do not include all the information needed to use RIABNI safely and effectively. See full prescribing information for RIABNI. RIABNI (rituximab-arrx) injection, for intravenous use Initial U.S. Approval: 2020 RIABNI (rituximab-arrx) is biosimilar to RITUXAN (rituximab)

Quick Stats

Total Products2

Labelers2

Label Sections39

Regulatory Agency

🇺🇸

U.S. Food and Drug Administration

United States

Data Sources & Disclaimer: Approval information is sourced from official FDA databases. This content is for informational purposes only and does not constitute medical or regulatory advice. Always refer to official FDA websites for the most current information.